Ionis Pharmaceuticals, Inc.
IONS

$5.59 B
Marketcap
$35.40
Share price
Country
$-0.52
Change (1 day)
$54.44
Year High
$33.33
Year Low
Categories

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

marketcap

Revenue of Ionis Pharmaceuticals, Inc. (IONS)

Revenue in 2023 (TTM): $787.65 M

According to Ionis Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $787.65 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Ionis Pharmaceuticals, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $787.65 M $778.51 M $-230,010,000 $-333,965,000 $-366,286,000
2022 $587 M $573 M $-227,758,000 $-258,000,000 $-270,000,000
2021 $810 M $799 M $-239,000 $-30,000,000 $-29,000,000
2020 $729 M $717 M $-107,882,000 $-170,000,000 $-487,000,000
2019 $1.12 B $1.12 B $411.53 M $347 M $294 M
2018 $599.67 M $597.85 M $-18,839,000 $-76,156,000 $273.74 M
2017 $507.67 M $133.02 M $39.8 M $-23,276,000 $-5,970,000
2016 $346.62 M $2.3 M $-8,827,000 $-83,622,000 $-86,556,000
2015 $283.7 M $-38,589,000 $-40,936,000 $-87,906,000 $-88,278,000
2014 $214.16 M $-27,590,000 $-22,778,000 $-54,391,000 $-38,984,000
2013 $147.29 M $-36,748,000 $-37,421,000 $-66,558,000 $-60,644,000
2012 $102.05 M $-56,409,000 $-42,680,000 $-74,587,000 $-65,478,000
2011 $99.09 M $99.09 M $-56,274,000 $-84,790,000 $-84,801,000
2010 $108.47 M $108.47 M $-38,750,000 $-61,159,000 $-61,251,000
2009 $121.6 M $121.6 M $-9,790,000 $-31,765,000 $155.07 M
2008 $107.19 M $107.19 M $4.11 M $-14,025,000 $-11,963,000
2007 $69.62 M $69.62 M $-26,154,000 $-10,994,000 $-10,994,000
2006 $24.53 M $24.53 M $-64,237,000 $-65,319,000 $-45,903,000
2005 $40.13 M $40.13 M $-42,400,000 $-72,401,000 $-72,401,000
2004 $42.62 M $42.62 M $-73,256,000 $-142,503,000 $-142,503,000
2003 $49.99 M $49.99 M $-64,922,000 $-94,996,000 $-94,996,000
2002 $80.18 M $80.18 M $-40,016,000 $-72,242,000 $-72,242,000
2001 $53.27 M $53.27 M $-39,135,000 $-73,832,000 $-73,832,000
2000 $37.26 M $42.79 M $-23,455,000 $-46,849,000 $-53,485,000
1999 $33.9 M $39.1 M $-37,900,000 $-50,300,000 $-59,200,000
1998 $39.2 M $43.5 M $-28,200,000 $-33,500,000 $-43,000,000
1997 $32.5 M $35.7 M $-28,100,000 $-27,400,000 $-31,100,000
1996 $22.6 M $25.2 M $-26,500,000 $-25,300,000 $-26,500,000
1995 $13 M $15.8 M $-22,800,000 $-22,600,000 $-23,700,000
1994 $10.1 M $13.9 M $-18,600,000 $-17,000,000 $-18,200,000
1993 $12.1 M $-10,300,000 $-15,100,000 $ $-19,100,000
1992 $8.7 M $10.7 M $-19,600,000 $-19,500,000 $-19,500,000
1991 $6.3 M $-5,200,000 $-9,600,000 $-8,700,000 $-8,700,000
1990 $2 M $-2,400,000 $-4,100,000 $ $-4,500,000